About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

TAIKO PHARMACEUTICAL CO., LTD.(4574) Summary

4574
TSE Prime
TAIKO PHARMACEUTICAL CO., LTD.
277
JPY
-3
(-1.07%)
May 1, 3:30 pm JST
1.92
USD
May 1, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
46.3
PBR
1.75
Yield
ー%
Margin Trading Ratio
17.26
Stock Price
May 1, 2025
Opening May 1, 9:00 am
279 JPY 1.95 USD
Previous Close Apr 30
280 JPY 1.96 USD
High May 1, 9:00 am
279 JPY 1.95 USD
Low May 1, 9:01 am
275 JPY 1.90 USD
Volume
85,300
Trading Value
0.02B JPY 0.16M USD
VWAP
276.8 JPY 1.92 USD
Minimum Trading Value
27,700 JPY 192 USD
Market Cap
0.01T JPY 0.10B USD
Number of Trades
132
Liquidity & Number of Trades
As of May 1, 2025
Liquidity
Mid
1-Year Average
271
1-Year High May 13, 2024
1,909
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 25, 2025 40,000 742,000 18.55
Apr 18, 2025 48,000 766,000 15.96
Apr 11, 2025 37,500 744,100 19.84
Apr 4, 2025 37,300 706,000 18.93
Mar 28, 2025 33,800 674,900 19.97
Company Profile
TAIKO PHARMACEUTICAL CO., LTD. manufactures and sells over-the-counter medicine "Seirogan" and infection control products "Cleverin". The company is expanding its overseas sales.
Sector
Pharmaceuticals
TAIKO PHARMACEUTICAL CO., LTD. operates in both the pharmaceutical and infection control sectors. In its pharmaceutical business, the company manufactures and sells over-the-counter medicines such as "Seirogan" and "Seirogan Sugar-coated A". While maintaining high brand recognition domestically, it is also expanding its distribution channels overseas, particularly in Hong Kong, China, and Taiwan. In the infection control business, the company develops "Cleverin" products using patented chlorine dioxide technology. These products target a wide range of customers, including general consumers, public institutions, and medical facilities. The company's other business activities include the production and sale of bath liquids and soaps containing wood vinegar, a byproduct of "Seirogan" manufacturing, as well as wood vinegar for gardening use. Through its domestic and international subsidiaries, TAIKO PHARMACEUTICAL CO., LTD. is advancing its global business expansion.